SCHEMBL7050141

SCHEMBL7050141

CC(C)CC(O)(C[PH](=O)CSc1ccc2ccccc2c1)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 1/20 0.39
EPHX1 P07099 1/20 0.39
SLC13A5 Q86YT5 1/20 0.38
GAA P10253 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
CAPN1 P07384 1/20 0.37
CTSB P07858 1/20 0.37
MAPT P10636 3/20 0.36
PTGER3 P43115 1/20 0.35
RAB9A P51151 1/20 0.34
ALDH1A1 P00352 4/20 0.34
HPGD P15428 1/20 0.34
CNR2 P34972 1/20 0.34
LMNA P02545 2/20 0.34
STAT3 P40763 1/20 0.34
POLB P06746 1/20 0.34
LNPEP Q9UIQ6 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7050051 0.88 SMN1; SMN2 (0.42) GAASMN1; SMN2MAPTALDH1A1HPGD
SCHEMBL7051737 0.83 SLC13A5 (0.41) ANPEPSLC13A5GAASMN1; SMN2MAPT
SCHEMBL7049626 0.81 SLC13A5 (0.51) ANPEPSLC13A5GAAMAPTALDH1A1
SCHEMBL7050255 0.81 PRNP (0.47) GAASMN1; SMN2MAPTRAB9AALDH1A1
SCHEMBL7051275 0.81 HPGD (0.39) ANPEPGAASMN1; SMN2MAPTALDH1A1
SCHEMBL7047099 0.80 SLC13A5 (0.44) ANPEPSLC13A5GAAMAPTALDH1A1
SCHEMBL7052621 0.78 MAPT (0.39) ANPEPEPHX1SLC13A5MAPT
SCHEMBL7050118 0.76 ALDH1A1 (0.34) ANPEPEPHX1GAACAPN1CTSB
SCHEMBL7441938 0.73 ANPEP (0.39) ANPEPEPHX1SLC13A5GAASMN1; SMN2
SCHEMBL8529953 0.70 ANPEP (0.36) ANPEPEPHX1GAACAPN1CTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212067-A1 Matrix metalloprotease inhibitors CASTELHANO ARLINDO LUCAS (US) 2003-11-13 US disclosed
US-6579890-B1 Matrix metalloprotease inhibitors SYNTEX (U.S.A.) INC. 2003-06-17 US disclosed
US-6037472-A FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS SYNTEX (U.S.A.) INC. (US) 2000-03-14 US disclosed
EP-0793643-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1997-09-10 EP disclosed
WO-1996016027-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1996-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212067-A1 Matrix metalloprotease inhibitors MMP7, MMP1, MMP3 ANPEP 154/4885EPHX1 791/4885SLC13A5 2127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.